Leerink Partners analyst David Risinger reiterated a Market Perform rating and $83.00 price target on Halozyme Therapeutics (NASDAQ: HALO)The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE